Understand the source comparison
How to Use Peptides for Gut Health: Peptide Comparison
Before selecting a peptide, understand how each compound differs in mechanism, target tissue, administration route, and evidence base. BPC-157 VEGF upregulation, angiogenesis, nitric oxide stabilization Mucosal injury, IBD, NSAID ulcers 200–500 mcg/day SC or o
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before selecting a peptide, understand how each compound differs in mechanism, target tissue, administration route, and evidence base.
- BPC-157
- VEGF upregulation, angiogenesis, nitric oxide stabilization
- Mucosal injury, IBD, NSAID ulcers
- 200–500 mcg/day
- SC or oral
- Animal models (strong), human trials (limited)
- Best for structural repair and tissue regeneration. Mechanism well-characterized but human dosing extrapolated from animal data
- KPV
- NF-κB inhibition, cytokine suppression
- Ulcerative colitis, colonic inflammation
- 500 mcg–2 mg/day
- SC, intranasal, or encapsulated oral
- Preclinical and Phase 2 trials
- Most specific for inflammatory pathways in the colon. Requires protected delivery for oral efficacy
- Thymosin Alpha-1
- Immune modulation, T-cell reprogramming
- Immune-mediated gut conditions, chronic infections
- 1.6 mg twice weekly
- SC
- Clinical trials in hepatitis and sepsis; emerging GI applications
- Addresses immune dysregulation, not acute inflammation. Works over weeks to months
- LL-37
- Antimicrobial peptide, microbiome modulation
- Dysbiosis, pathogenic bacterial overgrowth
- Research-stage dosing
- Topical or experimental
- In vitro and animal models
- Targets microbial balance rather than barrier integrity. Commercial formulations not yet standardized
- KPV 5MG
- NF-κB pathway suppression
- Inflammatory bowel pathology
- SC or encapsulated
- Phase 2 IBD trials
- Research-grade KPV from Real Peptides ensures verified sequencing and purity for consistent experimental outcomes